ArticleDrugs - real world outcomes2026
Characteristics and Treatment Patterns of Early Stage Melanoma: Results from a Multisite Chart Review.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly stage melanomas are clinically heterogeneous and real-world treatment patterns in early stage cutaneous melanoma are poorly characterized.
objectiveThe purpose of this study was to characterize real-world treatment patterns among patients with early stage cutaneous melanoma.
methodsA retrospective chart review was conducted at four US sites. Adult patients with histologically confirmed stage IB-IIC melanoma diagnosed between 1 January 2018 and 24 months before the start of data collection at each site (latest 3 July 2024) were included. Data on treatment patterns, recurrence, and lines of treatment (LOTs) were collected using a case report form (CRF). Treatment patterns were analyzed for specific sequences given within the same LOT. Chi-squared or Fisher's exact tests were used to assess associations.
resultsAmong 398 enrolled patients, 224 (56.3%) were stage IB, 84 (21.1%) IIA, 65 (16.3%) IIB, and 25 (6.3%) IIC. Overall, 366 (92.0%) received sentinel lymph node biopsy, 392 (98.5%) received surgery, 135 (33.9%) watchful waiting, 49 (12.3%) systemic drug therapy, and 10 (2.5%) radiotherapy. Radiotherapy and systemic drug therapy use was significantly greater in patients with higher stages or recurrence. The most frequent systemic drug therapies were anti-PD-1 (81.6%) and anti-CTLA-4 (30.6%). A total of 394 (99.0%) patients received at least one LOT. Almost all patients (99.5%) received surgery alone or in combination as the first LOT. Systemic drug therapy was included in most second LOTs (57.8%). Overall, 64 (16.1%) patients received ≥ 2 LOTs (stage IB 8.9%, IIA 22.7%, IIB 23.1%, IIC 40.0%) and 25 (6.3%) received ≥ 3 LOTs (stage IB 3.1%, IIA 7.2%, IIB 10.8%, IIC 20.0%).
conclusionsIn alignment with National Comprehensive Cancer Network (NCCN) guidelines, management of early stage cutaneous melanoma was predominantly surgical. Patients with higher disease stages received more LOTs, and some patients received up to four systemic drug therapies. This highlights a need for novel therapies and optimization of treatment sequences for high-risk early stage melanoma.
Identifiers
42762387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.